Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Diagnosis: Breast: Metastatic
NCT ID: NCT01701050
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-530
Utilizing CellSearch® technology, the ability to both enumerate and reliably and reproducibly characterize circulating tumor cells (CTC) for tumor markers that predict endocrine sensitivity (estrogen receptor [ER] and Bcl-2) and resistance (HER2 and Ki67) has been demonstrated. An algorithm for a CTC-Endocrine Therapy Index (CTC-ETI) has been constructed that can be calculated for each patient using the CTC enumeration and marker results. The primary goal of this study is to determine a CTC-ETI in ER positive, HER2 negative metastatic breast cancer patients before the initiation of a new endocrine therapy for the identification of patients that will progress rapidly.
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital
Ian Krop, MD,
Dana-Farber Cancer Institute
Aditya Bardia MD, MPH,
Massachusetts General Hospital
Dana-Farber Cancer Institute:
Breast Cancer Nursing Team, 617-632-3478
Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100
- Signed informed consent.
- Women who are 18 years or older.
- Patients must have estrogen receptor (ER) positive, HER2 negative metastatic breast
cancer (MBC) with at least one non-irradiated distant site of metastasis.
- ECOG performance status of 0-2.
- Patients must have currently progressive metastatic disease according to RECIST v1.1
- They have progressed on at least one previous line of endocrine therapy (ET) for
their metastatic disease (but are not currently progressing on fulvestrant), OR;
- They show evidence of disease progression during or within 12 months of the end
of adjuvant ET.
- Patient is about to start a new line of ET for their metastatic disease
- Patient is willing and able to undergo standard of care imaging studies (same
imaging/staging modality being used at each evaluation), which are anticipated to be
performed prior to the initiation of therapy and subsequently every 3 months.
- Patient agrees to the collection and testing of their blood and is willing and able
to provide approximately 40mL blood draw(s) at:
- Baseline (prior to the initiation of new ET), and;
- Subsequently at 1, 2, 3 and 12 months after the initiation of therapy, and/or;
- Time of disease progression.
- Patients with local regional recurrence only or brain only metastasis.
- Patients who are progressing on current fulvestrant therapy (patients who have had
fulvestrant therapy in the past and were subsequently treated with other therapies or
those who are starting fulvestrant as their next line of ET are eligible for the
- Patients who are or will be taking other unapproved (i.e. not cleared/approved by the
FDA) anti-neoplastic therapies concurrently are not eligible (exception: ET with
everolimus is acceptable).
- Patients with concomitant malignancies or previous malignancies within the last 5
years, with exception of adequately treated basal or squamous cell carcinoma of the
skin or carcinoma in situ of the cervix.
- Unable to provide informed consent or high risk that patient may not comply with
protocol requirements (i.e. due to health and/or participation in other research